Replies to post #1676 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

Ok—I’m convinced! In the calculation of RVNC’s 9/30/20 pro forma net cash that I will repost, I’ll reduce net cash by the full $4M milestone payment due on FDA approval of Daxi (not the $3.2M probability-weighted figure on the balance sheet).

Thank you for taking the time to clarify this matter.